peptides for focus
semax and selank are russian-academy prescription drugs with three decades of clinical use. dihexa is a wsu rodent paper with a c-met problem. those are not the same category.
the russian academy of sciences myasoedov institute developed semax (an acth 4-10 analog) and selank (a tuftsin analog) in the late 1980s. both are registered prescription drugs in russia with decades of clinical experience and bdnf or gabaergic mechanistic data, though no fda-grade phase-3 trial program. dihexa is the opposite profile: a 2012 paper from joseph harding's lab at washington state university showing rodent synaptogenesis via the c-met/hepatocyte-growth-factor pathway, zero human trials, and the same pathway is the target of oncology drugs because it drives tumor growth.
russian prescription status, a US wakefulness indication, an acute task signal, and a rodent paper are different evidence lanes. none alone proves broad cognitive enhancement in rested people.
patient-neurology evidence, illness-related fatigue studies, preclinical antidepressant work, and an unresolved marketed identity do not become healthy-person cognitive-enhancement evidence.
the nootropic core.
compounds with documented cognitive, anxiolytic, or neuroimmune signal in the russian and eastern-european clinical record.
- semax (tier B) · acth(4-10) heptapeptide analog, russian academy of sciences myasoedov institute, late 1980s.
- selank (tier B) · tuftsin analog from the same myasoedov lab as semax, anxiolytic profile.
- dsip (tier C) · delta sleep-inducing peptide, nonapeptide first isolated from rabbit brain dialysate in 1977.
- pinealon (tier C) · khavinson-program tripeptide (glu-asp-arg), st. petersburg institute of bioregulation and gerontology.
established pharmacology does not prove rested-person cognition.
approved uses, acute task signals, preclinical data, indirect mechanisms, and pathway-safety questions remain different evidence lanes.
- nad+ (tier D) · not a peptide. dinucleotide cofactor central to mitochondrial energy metabolism, sold by iv infusion clinics.
- epithalon (tier C) · russian longevity tetrapeptide (ala-glu-asp-gly) from the khavinson program.
- dihexa (tier D) · angiotensin iv analog, joseph harding lab at washington state university, 2012 synaptogenesis paper.
- Methylene blue (tier A) · Methylene blue is a redox-active phenothiazinium drug. Its FDA approval treats acquired methemoglobinemia; cognition evidence is a small acute experiment, not a chronic nootropic program.
- Modafinil (tier A) · Modafinil is an oral Schedule IV wake-promoting drug approved for excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift-work disorder. Those indications do not establish broad cognitive enhancement in rested healthy people.
- pe-22-28 (tier C) · a seven amino acid peptide researched as an antidepressant, so far only in mice and in cells. three papers, one lab, zero humans, and the 23 hour duration printed on vendor pages was measured on a different molecule.
- cerebrolysin (tier D) · a liquid made from pig brain, dripped into a vein in hospital after a stroke or in dementia. thousands of randomised patients have been given it. every dose in every trial is measured in millilitres, because the ampoule holds a mixture and there is no single molecule to weigh, and the only published identity test is a fingerprint match against a reference sample.
- adamax (tier D) · a marketed nootropic name whose exact chemical identity is not established by a cited primary characterisation. scoped PubMed and ClinicalTrials.gov searches found no exact-compound record.
- bromantane (tier B) · a Russian antiasthenic CNS drug with older human studies in illness-related fatigue, incomplete modern replication, no traceable primary human half-life source, and in-competition WADA prohibition.
- Noopept (omberacetam; GVS-111) (tier B) · omberacetam, a small-molecule cognitive drug sold as a registered 10 mg oral tablet in Russia. the cited human signal comes from one small patient comparison, not a healthy-user trial.
specific-question reference.
which nootropic peptide has the most concrete evidence?
semax. registered russian prescription for stroke and cognitive disorders since the 1990s, bdnf-upregulation mechanism, decades of myasoedov-lab and downstream clinical work. selank follows for anxiety and stress endpoints. neither has fda-grade phase-3 data, so confidence is not equivalent to an approved u.s. medication.
is dihexa a peptide?
borderline. it is a small-molecule angiotensin iv analog, hexamer-derived, not a standard amide-linked peptide drug. the reputation traces to harding's 2012 wsu rodent synaptogenesis paper. zero human cognitive trials.
does dsip improve focus?
not in the published record. the trial signal is on sleep and stress, mostly from the 1980s. any focus claim is a downstream sleep-quality hypothesis, not a primary cognitive effect.
what does the page avoid?
stack advice, psychiatric self-treatment framing, or claims that a peptide can replace sleep, diagnosis, therapy, or prescribed medication.
what the safety literature reports.
what safety gap matters most?
lack of modern, well-powered human trials for most of these compounds. absence of dramatic community harm reports is not a formal safety dataset.
why is dihexa treated cautiously?
the c-met/hepatocyte-growth-factor pathway is the same target as approved tumor-suppressing oncology drugs (capmatinib, tepotinib). agonizing it for cognition in rodents is interesting biology. doing it chronically in humans without trial data is a different proposition.
why does regulation matter?
russian prescription use, u.s. research-chemical availability, and fda approval are different categories. semax has the first, has the second in the u.s. peptide market, and does not have the third. they should not be conflated.
claim checks
related comparisons
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.